Literature DB >> 17151096

Quantitating the magnitude of the lymphocytic choriomeningitis virus-specific CD8 T-cell response: it is even bigger than we thought.

David Masopust1, Kaja Murali-Krishna, Rafi Ahmed.   

Abstract

Measuring the magnitudes and specificities of antiviral CD8 T-cell responses is critical for understanding the dynamics and regulation of adaptive immunity. Despite many excellent studies, the accurate measurement of the total CD8 T-cell response directed against a particular infection has been hampered by an incomplete knowledge of all CD8 T-cell epitopes and also by potential contributions of bystander expansion among CD8 T cells of irrelevant specificities. Here, we use several techniques to provide a more complete accounting of the CD8 T-cell response generated upon infection of C57BL/6 mice with lymphocytic choriomeningitis virus (LCMV). Eight days following infection, we found that 85 to 95% of CD8 T cells exhibit an effector phenotype as indicated by granzyme B, 1B11, CD62L, CD11a, and CD127 expression. We demonstrate that CD8 T-cell expansion is due to cells that divide >7 times, whereas heterologous viral infections only elicited <3 divisions among bystander memory CD8 T cells. Furthermore, we found that approximately 80% of CD8 T cells in spleen were specific for ten different LCMV-derived epitopes at the peak of primary infection. These data suggest that following a single LCMV infection, effector CD8 T cells divide > or =15 times and account for at least 80%, and possibly as much as 95%, of the CD8 T-cell pool. Moreover, the response targeted a very broad array of peptide major histocompatibility complexes (MHCs), even though we examined epitopes derived from only two of the four proteins encoded by the LCMV genome and C57BL/6 mice only have two MHC class I alleles. These data illustrate the potential enormity, specificity, and breadth of CD8 T-cell responses to viral infection and demonstrate that bystander activation does not contribute to CD8 T-cell expansion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17151096      PMCID: PMC1797597          DOI: 10.1128/JVI.01459-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  60 in total

1.  Induction of bystander T cell proliferation by viruses and type I interferon in vivo.

Authors:  D F Tough; P Borrow; J Sprent
Journal:  Science       Date:  1996-06-28       Impact factor: 47.728

2.  Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes.

Authors:  J E Gairin; H Mazarguil; D Hudrisier; M B Oldstone
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

3.  Cross-reactivities in memory cytotoxic T lymphocyte recognition of heterologous viruses.

Authors:  L K Selin; S R Nahill; R M Welsh
Journal:  J Exp Med       Date:  1994-06-01       Impact factor: 14.307

4.  Reduction of otherwise remarkably stable virus-specific cytotoxic T lymphocyte memory by heterologous viral infections.

Authors:  L K Selin; K Vergilis; R M Welsh; S R Nahill
Journal:  J Exp Med       Date:  1996-06-01       Impact factor: 14.307

5.  Lymphocytic choriomeningitis virus infection is associated with long-standing perturbation of LFA-1 expression on CD8+ T cells.

Authors:  E C Andersson; J P Christensen; A Scheynius; O Marker; A R Thomsen
Journal:  Scand J Immunol       Date:  1995-07       Impact factor: 3.487

6.  Phenotypic analysis of antigen-specific T lymphocytes.

Authors:  J D Altman; P A Moss; P J Goulder; D H Barouch; M G McHeyzer-Williams; J I Bell; A J McMichael; M M Davis
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

7.  CD8+ T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection.

Authors:  Jean-Marc Doisne; Alejandra Urrutia; Christine Lacabaratz-Porret; Cécile Goujard; Laurence Meyer; Marie-Laure Chaix; Martine Sinet; Alain Venet
Journal:  J Immunol       Date:  2004-08-15       Impact factor: 5.422

8.  Essential role of bystander cytotoxic CD122+CD8+ T cells for the antitumor immunity induced in the liver of mice by alpha-galactosylceramide.

Authors:  Ryusuke Nakagawa; Takuo Inui; Ikuko Nagafune; Yoshiko Tazunoki; Kazuhiro Motoki; Akira Yamauchi; Mitsuomi Hirashima; Yoshiko Habu; Hiroyuki Nakashima; Shuhji Seki
Journal:  J Immunol       Date:  2004-06-01       Impact factor: 5.422

9.  In vivo state of antiviral CTL precursors. Characterization of a cycling cell population containing CTL precursors in immune mice.

Authors:  E S Razvi; R M Welsh; H I McFarland
Journal:  J Immunol       Date:  1995-01-15       Impact factor: 5.422

10.  Antigen-independent activation of naive and memory resting T cells by a cytokine combination.

Authors:  D Unutmaz; P Pileri; S Abrignani
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

View more
  68 in total

1.  Regulation of innate CD8+ T-cell activation mediated by cytokines.

Authors:  Bailey E Freeman; Erika Hammarlund; Hans-Peter Raué; Mark K Slifka
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-04       Impact factor: 11.205

Review 2.  Coverage of related pathogenic species by multivalent and cross-protective vaccine design: arenaviruses as a model system.

Authors:  Jason Botten; John Sidney; Bianca R Mothé; Bjoern Peters; Alessandro Sette; Maya F Kotturi
Journal:  Microbiol Mol Biol Rev       Date:  2010-06       Impact factor: 11.056

3.  Inflammatory IL-15 is required for optimal memory T cell responses.

Authors:  Martin J Richer; Lecia L Pewe; Lisa S Hancox; Stacey M Hartwig; Steven M Varga; John T Harty
Journal:  J Clin Invest       Date:  2015-08-04       Impact factor: 14.808

4.  Use of the CD107 mobilization assay reveals that cytotoxic T lymphocytes with novel MHC-Ib restriction are activated during Listeria monocytogenes infection.

Authors:  Denise S McElroy; Adina M Badstibner; Sarah E F D'Orazio
Journal:  J Immunol Methods       Date:  2007-08-30       Impact factor: 2.303

5.  Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude.

Authors:  James J Moon; H Hamlet Chu; Marion Pepper; Stephen J McSorley; Stephen C Jameson; Ross M Kedl; Marc K Jenkins
Journal:  Immunity       Date:  2007-08-16       Impact factor: 31.745

Review 6.  Lymphocytic choriomeningitis virus-induced central nervous system disease: a model for studying the role of chemokines in regulating the acute antiviral CD8+ T-cell response in an immune-privileged organ.

Authors:  Allan Randrup Thomsen
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

7.  Recombinant LCMV Vectors Induce Protective Immunity following Homologous and Heterologous Vaccinations.

Authors:  Jessica Wingerath; Dmitrij Ostroumov; Norman Woller; Michael P Manns; Daniel D Pinschewer; Klaus Orlinger; Ursula Berka; Florian Kühnel; Thomas C Wirth
Journal:  Mol Ther       Date:  2017-07-20       Impact factor: 11.454

8.  Long-lived regulatory T cells generated during severe bronchiolitis in infancy influence later progression to asthma.

Authors:  Jason P Lynch; Rhiannon B Werder; Bodie F Curren; Md Al Amin Sikder; Ashik Ullah; Ismail Sebina; Ridwan B Rashid; Vivian Zhang; John W Upham; Geoff R Hill; Raymond J Steptoe; Simon Phipps
Journal:  Mucosal Immunol       Date:  2020-02-17       Impact factor: 7.313

9.  Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania.

Authors:  Blaise Dondji; Eszter Deak; Karen Goldsmith-Pestana; Eva Perez-Jimenez; Mariano Esteban; Sachiko Miyake; Takashi Yamamura; Diane McMahon-Pratt
Journal:  Eur J Immunol       Date:  2008-03       Impact factor: 5.532

10.  Lymphocytic choriomeningitis virus infection yields overlapping CD4+ and CD8+ T-cell responses.

Authors:  Courtney Dow; Carla Oseroff; Bjoern Peters; Courtney Nance-Sotelo; John Sidney; Michael Buchmeier; Alessandro Sette; Bianca R Mothé
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.